The pathophysiology of secondary hyperparathyroidism and the consequences of uncontrolled mineral metabolism in chronic kidney disease: The role of cosmos

NDT Plus

Volumn 1, Issue SUPPL.1, 2008, Pages

  Cannata Andía, Jorge B ^a   Carrera, Fernando ^b  

^a UNIVERSITY OF OVIEDO   (Spain)

^b Dialysis Unit   (Portugal)

Author keywords

Calcium; Haemodialysis; Kidney; Phosphorus; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; HEMODIALYSIS PATIENT; HUMAN; MINERAL METABOLISM; MORTALITY; PARATHYROID FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM;

EID: 39349110001     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfm037     Document Type: Conference Paper

References (52)

1. Almaden Y, Hernandez A, Torregrosa V et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998; 9: 1845-1852
2. Slatopolsky E, Finch J, Denda M et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534-2540
3. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol 2005; 288: F253-F264
4. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997; 29: 496-502
5. Owda Al Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: Prevalence and race. Ren Fail 2003; 25: 595-602
6. Salem MM. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients. Am J Kidney Dis 1997; 29: 862-865
7. de Francisco AL. Medical therapy of secondary hyperparathyroidism in chronic kidney disease: Old and new drugs. Expert Opin Pharmacother 2006; 7: 2215-2224
8. Rodriguez M, Canalejo A, Garfia B, Aguilera E, Almaden Y. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int Suppl 2002: 155-160
9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
10. Braun J, Oldendorf M, Moshage W, Heidler R, Reitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401
11. Tokuyama T, Ikeda T, Sato K, Mimura O, Morita A, Tabata T. Conjunctival and corneal calcification and bone metabolism in hemodialysis patients. Am J Kidney Dis 2002; 39: 291-296
12. Elder G. Pathophysiology and recent advances in the management of renal osteodystropby. J Bone Miner Res 2002; 17: 2094-2105
13. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995; 96: 1786-1793
14. 3. Kidney Int 1986; 30: 793-803
15. Panda DK, Miao D, Bolivar I et al. Inactivation of the 25-hydroxyvitamin D lalpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279: 16754-16766
16. Hoenderop JG, Muller D, Van Der Kemp AW et al. Calcitriol controls the epithelial calcium channel in kidney, J Am Soc Nephrol 2001; 12: 1342-1349
17. 3. Proc Natl Acad Sci U S A 1992; 89: 8097-8101
18. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986; 78: 1296-1301
19. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998; 273: 5253-5259
20. Bricker NS. On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". N Engl J Med 1972; 286: 1093-1099
21. Brent GA, LeBoff MS, Seely EW, Conlin PR, Brown EM. Relationship between the concentration and rate of change of calcium and serum intact parathyroid hormone levels in normal humans. J Clin Endocrinol Metab 1988; 67: 944-950
22. Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Disord 2000; 1: 307-315
23. Hanley DA, Takatsuki K, Sultan JM, Schneider AB, Sherwood LM. Direct releasc of parathyroid hormone fragments from functioning bovine parathyroid glands in vitro. J Clin Invest 1978; 62: 1247-1254
24. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990; 86: 1313-1319
25. Silver J, Moallem E, Kilav R, Sela A, Naveh-Many T. Regulation of the parathyroid hormone gene by calcium, phosphate and 1,25-dihydroxyvitamin D. Nephrol Dial Transplant 1998; 13(Suppl 1): 40-44
26. Kilav R, Silver J, Naveh-Many T. A conserved cis-acting element in the parathyroid hormone 3'-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate. J Biol Chem 2001; 276: 8727-8733
27. Sela-Brown A, Silver J, Brewer G, Naveh-Many T. Identification of AUF1 as a parathyroid hormone mRNA 3'-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem 2000; 275: 7424-7429
28. 3 receptor density is associated with a more severe fpim of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443
29. 2+-sensing receptor in primary and uremic secondary hyperpathyroidism. J Clin Endocrinol Metab 1996; 81: 1598-1606
30. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor ih parathyroid and tissue of pationts with hyper-parathyroidism. Kidney Int 1997; 51: 328-336
31. Silver J, Kilav R, Naveh-Many T. Mechanisms of second secondary hyperparathyroidism. Am J Physiol Renal Physiol 2002; 283: F367-F376
32. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
33. Belozeroff V, Klassen P, Wentworth C, Ofsthun N, Arab L, Rothman KJ, Effects of uncontrolled biochemical parameters on cardiovascular mortality in dialysis patients [Abstract SP253]. Nephrol Dial Transplant 2005; 20(Suppl 5): V103-v104
34. Naves M, Guinsburg A, Marelli C et al. Relative risk of death according to serum Ca, P, and PTH. Results from a large sample of dialysis patients from Latin America followed for up to 54 months. Presented at: Renal Week, 8-13 November 2005; Philadelphia, PA, USA
35. Block GA, Hulbert-Shearon T, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-617
36. Belozeroff V, Danese M, Smirnakis K, Rothman KJ. Association of parathyroid hormone (PTH), phosphorus (P), and calcium (Ca) KDOQI™ target achievement with mortality in patients on dialysis. Presented at: Renal Week, 8-13 November 2006; Philadelphia, PA, USA
37. Block GA, Klassen P, Danese M. Association between proposed NKFK/DOQI bone metabolism and disease guidelines and mortality risk in hemodialysis patients. J Am Soc Nephrol 2003; 14: 474A
38. Ishimura E, Taniwaki H, Tabata T et al. Cross-sectional association of serum phosphate with carotid intima-medial thickness in hemodialysis patients. Am J Kidney Dis 2005; 45: 859-865
39. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
40. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-2299
41. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17
42. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237
43. Shanahan CM, Proudfoot D, Farzaneh-Far A, Weissberg PL. The role of G1a proteins in vascular calcification. Crit Rev Eukaryot Gene Expr 1998; 8: 357-375
44. Rodriguez-Garcia M, Naves M, Cannata-Andía J. Bone metabolism, vascular calcifications and mortality: Associations beyond mere coincidence. J Nephrol 2005; 18: 458-463
45. Kim J, Dylan M, Doan Q et al. Association of elevated serum parathyroid hormone (PTH) and calcium with hip, vertebral, or pelvic fracture in hemodialysis patients [Abstract S026]. Presented at: ERA-EDTA Congress, 15-18 May 2004, Lisbon, Portugal
46. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
47. Cannata-Andía J, Fernández-Martin JL, Diaz-Corte C, for the ROD Multicenter Study. Applying the K/DOQI guidelines cut-off values to the dialysis population: How far are we from the target? J Am Soc Nephrol 2003; 14: 474A
48. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 34-38
49. Fernandez-Martin J, Ferreira A, Floege J et al. Results from the initial cross-sectional analysis of the COSMOS baseline population. Presented at: ERA-EDTA, 16-18 July, 2006; Glasgow, UK
50. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
51. Fernández-Martín J, Gorriz J, Ketteler M et al. Guidelines and bone mineral management in facilities in the pan-European COSMOS study. Presented at: ERA-EDTA, 16-18 July 2006; Glasgow, UK
52. Fernández-Martín J, Gorriz J, Ketteler M et al. Achievement of K/DOQI targets in European hemodialysis (HD) patients (Pts) in the COSMOS Study: Differences between prevalent and incident Pts. Presented at: Renal Week, 8-13 November, 2006; Philadelphia, PA, USA